Green Cross’ Hunterase receiving ‘New Treatment Award’
Green Cross’ Hunterase receiving ‘New Treatment Award’
  • by Lee Jae-seung(
  • 승인 2015.02.26 03:46
  • 댓글 0
이 기사를 공유합니다

Green Cross’( Hunterase is gaining attention in the field of cure for rare diseases where multinational pharmaceutical firms dominate. Hunterase breaks the monopoly market to become the world’s second successful cure for Hunter syndrome in 2012.

On February 23, Green Cross(President &CEO Huh, Eun Chul) announced that it received ‘New Treatment Award’ in the 11th Annual Lysosomal Disease Network WORLD Symposium held in Orlando, Florida from Feb. 9 to Feb. 13.

‘New Treatment Award’ is the award to be given to the medicine which makes great contribution to lysosomal diseases every year. It is considered unconventional that Hunterase was given the award before its launching in North America.

Lysosomal dieases develop in general when there is a lack of specific enzyme in lysosome, including Hunter syndrome, Gaucher disease, Fabry disease and Pompe's disease. The patients with these lysosomal diseases are treated with medicines enabling enzyme replacement therapy (ERT).

“The award was given since Hunterase is highly recommended for its superiority and contribution for enhancing the quality of life among those patients with lysosomal diseases,” said an official of Green Cross, “Doctors and groups of patients across the world are very interested in Hunterase.”

By Lee Jae-seung

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: / Editorial Div. 02-578-0434 / 010-2442-9446. Email:
  • Publisher: Monica Younsoo Chung. Chief Editorial Writer: Kim Hyoung-joong. CEO: Lee Kap-soo. Editor: Jung Yeon-jin.
  • Juvenile Protection Manager: Yeon Choul-woong. IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.